mardi 26 janvier 2021


IQVIA Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance

Par Rédaction , dans Communiqués , le 22 octobre 2018

Monday, October 22nd 2018 at 11:00am UTC
  • Revenue $2,594 million, up 6.3 percent at constant currency and 5.2
    percent reported
  • Adjusted EBITDA $561 million, up 8.4 percent at constant currency
    and 9.4 percent reported
  • GAAP Diluted Earnings per Share $0.29
  • Adjusted Diluted Earnings per Share $1.42, up 19.3 percent
  • $792 million of share repurchase completed year-to-date; $133
    million during the third quarter
  • Record quarter of R&D Solutions contracted services Net New
    Business, resulting in a book-to-bill ratio of 1.69x
  • Reaffirming mid-point of full-year 2018 revenue guidance inclusive
    of foreign currency headwind; raising mid-point of full-year 2018
    Adjusted EBITDA and Adjusted Diluted EPS guidance

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of
advanced analytics, technology solutions, and contract research services
to the life sciences industry, today reported financial results for the
quarter ended September 30, 2018. On January 1, 2018, IQVIA adopted ASC
606 “Revenue from Contracts with Customers” as required by the Financial
Accounting Standards Board. Under this new standard, IQVIA recognizes
revenue in the Research & Development Solutions segment on a percentage
of completion basis. Additionally, ASC 606 requires that service revenue
and reimbursed expense revenue be consistently presented as one line on
the income statement. Unless stated otherwise, all financial information
that follows has been provided under ASC 606.

Third-Quarter 2018 Operating Results

Revenue for the third quarter of $2,594 million increased 6.3 percent at
constant currency and 5.2 percent reported, compared to the third
quarter of 2017. Technology & Analytics Solutions (TAS) revenue of
$1,014 million grew 15.0 percent at constant currency and 12.9 percent
reported, including the benefit of acquisitions. Research & Development
Solutions (R&DS) revenue of $1,382 million grew 3.5 percent at constant
currency and 3.1 percent reported, with growth in R&DS substantially all
organic. Contract Sales & Medical Solutions (CSMS) revenue of $198
million declined 11.9 percent at constant currency and 12.8 percent
reported.

Third-quarter 2018 Adjusted EBITDA of $561 million increased 8.4 percent
at constant currency and 9.4 percent reported. GAAP net income was $60
million and GAAP diluted earnings per share was $0.29. Adjusted Net
Income of $294 million grew 13.1 percent, and Adjusted Diluted Earnings
per Share of $1.42 grew 19.3 percent.

“We delivered another quarter of strong financial performance, with
solid core growth in our R&DS and TAS segments,” said Ari Bousbib,
chairman and CEO of IQVIA. “In R&DS, we had a record quarter of
contracted services net new business, which positions us well to deliver
on our merger synergy targets exiting 2019. Our technology business
continues its strong momentum, driven by deals such as the recent
milestone agreement with Roche to deploy and use IQVIA commercial
technologies globally, and by the launch of our clinical technologies
suite, which we are developing on Salesforce.”

Year-to-Date 2018 Operating Results

Revenue of $7,724 million for the first nine months of 2018 increased
6.4 percent at constant currency and 7.6 percent reported, compared to
the first nine months of 2017. TAS revenue of $3,010 million grew 12.5
percent at constant currency and 13.8 percent reported. R&DS revenue of
$4,097 million grew 5.8 percent at constant currency and 6.8 percent
reported. CSMS revenue of $617 million declined 13.3 percent at constant
currency and 11.7 percent reported.

R&DS contracted backlog including reimbursed expenses was $16.4 billion
at September 30, 2018. The company expects approximately $4.6 billion of
this backlog to convert to revenue in the next twelve months. For
comparability during 2018, the company is reporting R&DS net new
business on a contracted basis excluding reimbursed expenses. Under this
approach, R&DS contracted net new business of $5.37 billion for the
twelve months ended September 30, 2018, grew 22.9 percent compared to
the twelve months ended September 30, 2017. R&DS contracted net new
business for the quarter ending September 30, 2018 was $1.7 billion,
representing a contracted book-to-bill ratio (excluding reimbursed
expenses) of 1.69 for the third quarter 2018.

Adjusted EBITDA of $1,641 million for the first nine months of 2018
increased 10.0 percent at constant currency and 10.6 percent reported.
GAAP net income was $190 million and GAAP diluted earnings per share was
$0.91. Adjusted Net Income of $849 million for the first nine months of
2018 grew 12.7 percent, and Adjusted Diluted Earnings per Share of $4.05
grew 21.3 percent compared to the first nine months of 2017.

Financial Position

As of September 30, 2018, cash and cash equivalents were $827 million
and debt was $10,619 million, resulting in net debt of $9,792 million.
At the end of the third quarter of 2018, IQVIA’s Gross Leverage Ratio
was 4.9 times, and Net Leverage Ratio was 4.5 times, trailing twelve
month Adjusted EBITDA.

Share Repurchase

During the third quarter, the company repurchased $133 million of its
stock in the open market, bringing year-to-date repurchases to $792
million. IQVIA had $889 million of share repurchase authorization
remaining as of September 30, 2018.

Full-Year 2018 Guidance

Guidance ranges for full-year 2018 have been updated. The revenue
guidance range has been reaffirmed at the mid-point of the range,
despite a foreign currency headwind of approximately $35 million. The
Adjusted EBITDA guidance has been increased by $10 million at the
mid-point of the range, and the Adjusted Diluted Earnings per Share
guidance has been increased by $0.05 at the mid-point of the range.
Full-year 2018 guidance updates are as follows:

($ millions, except per share data)                                                                                      
                                                                          Guidance                                                     VPY% AFx

Revenue(1)

$10,335 – $10,385                                                     6.5% – 7.0%
FX

~$(35)

Revenue(2)

$10,300 – $10,350 6.2% – 6.7%
 
Adjusted EBITDA $2,195 – $2,225 9.2% – 10.7%
 
Adjusted Diluted EPS $5.45 – $5.55 19.8% – 22.0%
                                                                                                                                   

1.

 

Assumes foreign currency exchange rates are consistent with
when guidance was provided on Q2 2018 earnings call

2.

Revenue guidance using current foreign currency exchange rates

 

This financial guidance assumes current foreign currency exchange rates
remain in effect for the remainder of the year.

Webcast & Conference Call Details

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to
discuss its third-quarter 2018 financial results. To participate, please
dial 1-800-901-1807 in the United States and Canada or +1-212-231-2924
outside the United States approximately 15 minutes before the scheduled
start of the call. The conference call and a presentation will be
accessible live via webcast on the Investors section of the IQVIA
website at http://ir.iqvia.com.
An archived replay of the webcast will be available online at http://ir.iqvia.com
after 1:00 p.m. Eastern Time today.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions, and contract research services to the life
sciences industry. Formed through the merger of IMS Health and
Quintiles, IQVIA applies human data science — leveraging the analytic
rigor and clarity of data science to the ever-expanding scope of human
science — to enable companies to reimagine and develop new approaches to
clinical development and commercialization, speed innovation, and
accelerate improvements in healthcare outcomes. Powered by the IQVIA
CORE™, IQVIA delivers unique and actionable insights at the intersection
of large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100 countries.

Cautionary Statements Regarding Forward Looking Statements

This press release contains “forward-looking statements” within the
meaning of the federal securities laws, including Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, including, without limitation, our
2018 guidance. In this context, forward-looking statements often address
expected future business and financial performance and financial
condition, and often contain words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,”
similar expressions, and variations or negatives of these words. Actual
results may differ materially from our expectations due to a number of
factors, including, but not limited to, the following: most of our
contracts may be terminated on short notice, and we may lose or
experience delays with large client contracts or be unable to enter into
new contracts; imposition of restrictions on our use of data by data
suppliers or their refusal to license data to us; any failure by us to
comply with contractual, regulatory or ethical requirements under our
contracts, including current or changes to data protection and privacy
laws; breaches or misuse of our or our outsourcing partners’ security or
communications systems; hardware and software failures, delays in the
operation of our computer and communications systems or the failure to
implement system enhancements; failure to meet our productivity or
business transformation objectives; failure to successfully invest in
growth opportunities; our ability to protect our intellectual property
rights and our susceptibility to claims by others that we are infringing
on their intellectual property rights; the expiration or inability to
acquire third party licenses for technology or intellectual property;
any failure by us to accurately and timely price and formulate cost
estimates for contracts, or to document change orders; the rate at which
our backlog converts to revenue; our ability to acquire, develop and
implement technology necessary for our business; consolidation in the
industries in which our clients operate; risks related to client or
therapeutic concentration; the risks associated with operating on a
global basis, including currency or exchange rate fluctuations and legal
compliance, including anti-corruption laws; risks related to changes in
accounting standards, including the impact of the changes to the revenue
recognition standards; general economic conditions in the markets in
which we operate, including financial market conditions and risks
related to sales to government entities; the impact of changes in tax
laws and regulations; and our ability to successfully integrate, and
achieve expected benefits from, our acquired businesses. For a further
discussion of the risks relating to the combined company’s business, see
the “Risk Factors” in our annual report on Form 10-K for the fiscal year
ended December 31, 2017, filed with the SEC, as such factors may be
amended or updated from time to time in our subsequent periodic and
other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.
These factors should not be construed as exhaustive and should be read
in conjunction with the other cautionary statements that are included in
this release and in our filings with the SEC. We assume no obligation to
update any such forward-looking statement after the date of this
release, whether as a result of new information, future developments or
otherwise.

Note on Non-GAAP Financial Measures

Non-GAAP results, such as Adjusted EBITDA, Adjusted Net Income, and
Adjusted Diluted EPS are presented only as a supplement to the company’s
financial statements based on GAAP. Non-GAAP financial information is
provided to enhance understanding of the company’s financial
performance, but none of these non-GAAP financial measures are
recognized terms under GAAP, and non-GAAP measures should not be
considered in isolation from, or as a substitute analysis for, the
company’s results of operations as determined in accordance with GAAP.
Definitions and reconciliations of non-GAAP measures to the most
directly comparable GAAP measures are provided within the schedules
attached to this release. The company uses non-GAAP measures in its
operational and financial decision making, and believes that it is
useful to exclude certain items in order to focus on what it regards to
be a more meaningful indicator of the underlying operating performance
of the business. As a result, internal management reports feature
non-GAAP measures which are also used to prepare strategic plans and
annual budgets and review management compensation. The company also
believes that investors may find non-GAAP financial measures useful for
the same reasons, although investors are cautioned that non-GAAP
financial measures are not a substitute for GAAP disclosures.

Our 2018 guidance measures (other than revenue) are provided on a
non-GAAP basis because the company is unable to reasonably predict
certain items contained in the GAAP measures. Such items include, but
are not limited to, acquisition and integration related expenses,
restructuring and related charges, stock-based compensation and other
items not reflective of the company’s ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors
and other interested parties in their evaluation of companies comparable
to the company, many of which present non-GAAP measures when reporting
their results. Non-GAAP measures have limitations as an analytical tool.
They are not presentations made in accordance with GAAP, are not
measures of financial condition or liquidity and should not be
considered as an alternative to profit or loss for the period determined
in accordance with GAAP or operating cash flows determined in accordance
with GAAP. Non-GAAP measures are not necessarily comparable to similarly
titled measures used by other companies. As a result, you should not
consider such performance measures in isolation from, or as a substitute
analysis for, the company’s results of operations as determined in
accordance with GAAP.

Click
here to subscribe to Mobile Alerts for IQVIA
.

IQVIAFIN

       
Table 1
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(in millions, except per share data)
(preliminary and unaudited)
 
 
Three Months Ended Nine Months Ended
September 30, September 30,
  2018 2017 2018 2017
Revenues $ 2,594 $ 2,466 $ 7,724 $ 7,181
Costs of revenue, exclusive of depreciation and amortization 1,678 1,611 5,004 4,694
Selling, general and administrative expenses 429 394 1,273 1,153
Depreciation and amortization 283 256 847 733
Impairment charges 40
Restructuring costs   23     10     66     38  
Income from operations 181 195 534 523
Interest income (2 ) (2 ) (5 ) (5 )
Interest expense 105 93 308 249
Loss on extinguishment of debt 18 2 21
Other expense (income), net   27         5     (3 )

Income before income taxes and equity in earnings of
unconsolidated affiliates

51 86 224 261
Income tax (benefit) expense   (14 )   (3 )   29     7  

Income before equity in earnings of unconsolidated affiliates

65 89 195 254
Equity in earnings of unconsolidated affiliates   2     4     13     7  
Net income 67 93 208 261
Net income attributable to non-controlling interests   (7 )   (5 )   (18 )   (11 )
Net income attributable to IQVIA Holdings Inc. $ 60   $ 88   $ 190   $ 250  
Earnings per share attributable to common stockholders:
Basic $ 0.30 $ 0.41 $ 0.93 $ 1.13
Diluted $ 0.29 $ 0.40 $ 0.91 $ 1.11
Weighted average common shares outstanding:
Basic 202.3 214.3 205.2 220.7
Diluted 206.8 219.0 209.6 225.4
 
       
Table 2
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in millions, except per share data)
(preliminary and unaudited)
 
 
September 30, December 31,
      2018 2017
ASSETS
Current assets:
Cash and cash equivalents $ 827 $ 959
Trade accounts receivable and unbilled services, net 2,298 2,097
Prepaid expenses 154 146
Income taxes receivable 66 47
Investments in debt, equity and other securities 52 46
Other current assets and receivables   299     259  
Total current assets   3,696     3,554  
Property and equipment, net 417 440
Investments in debt, equity and other securities 28 8
Investments in unconsolidated affiliates 106 70
Goodwill 11,794 11,850
Other identifiable intangibles, net 6,103 6,591
Deferred income taxes 96 109
Deposits and other assets   258     235  
Total assets $ 22,498   $ 22,857  
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses $ 2,162 $ 1,986
Unearned income 984 985
Income taxes payable 117 72
Current portion of long-term debt 101 103
Other current liabilities   16     10  
Total current liabilities 3,380 3,156
Long-term debt 10,518 10,122
Deferred income taxes 734 895
Other liabilities   406     440  
Total liabilities   15,038     14,613  
Commitments and contingencies
Stockholders’ equity:

Common stock and additional paid-in capital,

400.0 shares authorized at September 30, 2018 and December 31,
2017,
$0.01 par value, 251.2 and 249.5 shares issued at
September 30, 2018 and
December 31, 2017, respectively

10,876 10,782
Retained earnings 726 538

Treasury stock, at cost, 48.9 and 41.4 shares at September 30, 2018
  and
December 31, 2017, respectively

(4,167 ) (3,374 )
Accumulated other comprehensive (loss) income   (220 )   49  
Equity attributable to IQVIA Holdings Inc.’s stockholders 7,215 7,995
Non-controlling interests   245     249  
Total stockholders’ equity   7,460     8,244  
Total liabilities and stockholders’ equity $ 22,498   $ 22,857  
 
       
Table 3
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(preliminary and unaudited)
 
 
Nine Months Ended
September 30,
  2018 2017
Operating activities:
Net income $ 208 $ 261
Adjustments to reconcile net income to cash provided by operating
activities:
Depreciation and amortization 847 733
Amortization of debt issuance costs and discount 8 6

Amortization of accumulated other comprehensive loss on terminated
  interest
rate swaps

3
Stock-based compensation 78 82
Impairment of goodwill and identifiable intangible assets 40
(Earnings) loss from unconsolidated affiliates (13 ) 4
Gain on investments, net (3 )
Benefit from deferred income taxes (183 ) (137 )
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income (219 ) (104 )
Change in other operating assets and liabilities   114     (151 )
Net cash provided by operating activities 837 737
Investing activities:
Acquisition of property, equipment and software (321 ) (267 )
Acquisition of businesses, net of cash acquired (255 ) (525 )
Disposition of business, net of cash disposed 12
Purchase of marketable securities (3 )
Investments in unconsolidated affiliates, net of payments received (24 ) 5
Investments in equity securities (23 )
Other   (6 )   1  
Net cash used in investing activities (632 ) (774 )
Financing activities:
Proceeds from issuance of debt 1,631 5,242
Payment of debt issuance costs (23 ) (53 )
Repayment of debt and principal payments on capital lease obligations (707 ) (2,858 )
Proceeds from revolving credit facility 1,800 1,222
Repayment of revolving credit facility (2,169 ) (1,497 )
Proceeds related to employee stock option plans 18 86
Repurchase of common stock (801 ) (2,252 )
Distributions to non-controlling interests, net (19 ) (3 )

Contingent consideration and deferred purchase price payments

  (24 )   (4 )
Net cash used in financing activities (294 ) (117 )
Effect of foreign currency exchange rate changes on cash   (43 )   59  
Decrease in cash and cash equivalents (132 ) (95 )
Cash and cash equivalents at beginning of period   959     1,198  
Cash and cash equivalents at end of period $ 827   $ 1,103  
 
       
Table 4
IQVIA HOLDINGS INC. AND SUBSIDIARIES
NET INCOME TO ADJUSTED EBITDA RECONCILIATION
(in millions)
(preliminary and unaudited)
 
 
Three Months Ended Nine Months Ended
September 30, September 30,
  2018 2017 2018 2017
Net Income $ 60 $ 88 $ 190 $ 250
Provision for income taxes (14 ) (3 ) 29 7
Depreciation and amortization 283 256 847 733
Interest expense, net 103 91 303 244
Income in unconsolidated affiliates (2 ) (4 ) (13 ) (7 )
Income from non-controlling interests 7 5 18 11
Deferred revenue purchasing accounting adjustments 3 1 6 10
Stock-based compensation 31 29 78 82
Other expense, net 36 5 27 15
Loss on extinguishment of debt 18 2 21
Impairment charges 40
Restructuring and related charges 23 10 66 38
Acquisition related charges 12 9 38 27
Integration related costs   19     8     50     13  
Adjusted EBITDA $ 561   $ 513   $ 1,641   $ 1,484  
 

Note:  Numbers may not add to total due to rounding.

 
       
Table 5
IQVIA HOLDINGS INC. AND SUBSIDIARIES
NET INCOME TO ADJUSTED NET INCOME RECONCILIATION
(in millions, except per share data)
(preliminary and unaudited)
 
Three Months Ended Nine Months Ended
September 30, September 30,
  2018 2017 2018 2017
Net Income $ 60 $ 88 $ 190 $ 250
Provision for income taxes (14 ) (3 ) 29 7
Purchase accounting amortization 216 193 651 553
Income in unconsolidated affiliates (2 ) (4 ) (13 ) (7 )
Income from non-controlling interests 7 5 18 11
Deferred revenue purchasing accounting adjustments 3 1 6 10
Stock-based compensation 31 29 78 82
Other expense, net 36 5 27 15
Loss on extinguishment of debt 18 2 21
Impairment charges 40
Royalty hedge (gain) loss 3 1 (2 ) 8
Restructuring and related charges 23 10 66 38
Acquisition related charges 12 9 38 27
Integration related costs   19     8     50     13  
Adjusted Pre Tax Income $ 394 $ 361 $ 1,140 $ 1,068
Adjusted tax expense (91 ) (94 ) (266 ) (297 )
Income from non-controlling interests (7 ) (5 ) (18 ) (11 )
Minority interest effect in non-GAAP adjustments (1)   (2 )   (2 )   (7 )   (7 )
Adjusted Net Income $ 294   $ 260   $ 849   $ 753  
 
Adjusted earnings per share attributable to common shareholders:
Basic $ 1.45 $ 1.21 $ 4.14 $ 3.41
Diluted $ 1.42 $ 1.19 $ 4.05 $ 3.34
Weighted-average common shares outstanding:
Basic 202.3 214.3 205.2 220.7
Diluted 206.8 219.0 209.6 225.4
 
(1) Reflects the portion of Q2 Solutions’
after-tax non-GAAP adjustments attributable to the minority interest
partner.
 
Note: Numbers may not add to total due to rounding.
 
   
Table 6
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CALCULATION OF GROSS AND NET LEVERAGE RATIOS
AS OF SEPTEMBER 30, 2018
(in millions)
(preliminary and unaudited)
 
 
       
Gross Debt, net of Original Issue Discount, as of September 30, 2018 $ 10,619
Net Debt as of September 30, 2018     $ 9,792
Adjusted EBITDA for the twelve months ended September 30, 2018 $ 2,167
Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA) 4.9x
Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA)     4.5x
 

Contacts

IQVIA
Investor Relations
Andrew Markwick, +1 973-257-7144
andrew.markwick@iqvia.com
or
Media
Relations
Tor Constantino, +1 484-567-6732
tor.constantino@iqvia.com

Source: IQVIA Holdings Inc.

Étiquettes :